Clinical Endoscopy

  • 제51권4호
  • /
  • Pages.344-351
  • /
  • 2018
  • /
  • 2234-2400(pISSN)
  • /
  • 2234-2443(eISSN)
대한소화기내시경학회 (The Korean Society of Gastrointestinal Endoscopy)
권호 표지
DOI QR코드

DOI QR Code

Quality Indicators in Barrett's Esophagus: Time to Change the Status Quo

  • Han, Samuel (Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Center) ;
  • Wani, Sachin (Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Center)
  • 투고 : 2018.05.30
  • 심사 : 2018.06.13
  • 발행 : 2018.07.30
⟨ 이전 논문 다음 논문 ⟩

초록

The push for high quality care in all fields of medicine highlights the importance of establishing and adhering to quality indicators. In response, several gastrointestinal societies have established quality indicators specific to Barrett's esophagus, which serve to create thresholds for performance while standardizing practice and guiding value-based care. Recent studies, however, have consistently demonstrated the lack of adherence to these quality indicators, particularly in surveillance (appropriate utilization of endoscopy and obtaining biopsies using the Seattle protocol) and endoscopic eradication therapy practices. These findings suggest that innovative interventions are needed to address these shortcomings in order to deliver high quality care to patients with Barrett's esophagus.

키워드

과제정보

연구 과제 주관 기관 : University of Colorado

참고문헌

  1. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014;63:7-42. https://doi.org/10.1136/gutjnl-2013-305372
  2. Wani S, Falk GW, Post J, et al. Risk factors for progression of lowgrade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011;141:1179-1186, 1186.e1. https://doi.org/10.1053/j.gastro.2011.06.055
  3. Thrift AP. Barrett's esophagus and esophageal adenocarcinoma: how common are they really? Dig Dis Sci 2018;63:1988-1996. https://doi.org/10.1007/s10620-018-5068-6
  4. Sharma P, Katzka DA, Gupta N, et al. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015;149:1599-1606. https://doi.org/10.1053/j.gastro.2015.08.007
  5. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Gastrointest Endosc 2017;86:1-17.e3. https://doi.org/10.1016/j.gie.2017.03.010
  6. Wani S, Muthusamy VR, Shaheen NJ, et al. Development of quality indicators for endoscopic eradication therapies in Barrett's esophagus: the TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium. Am J Gastroenterol 2017;112:1032-1048. https://doi.org/10.1038/ajg.2017.166
  7. Institute of Medicine (US). America's health in transition: protecting and improving quality. Washington, D.C.: National Academies Press (US);1994.
  8. Rubenstein JH, Lieberman D, Fennerty B, Gellad ZF. Measuring the quality of Barrett's esophagus management with measures that are high quality. Gastroenterology 2015;149:1298-1301. https://doi.org/10.1053/j.gastro.2015.09.006
  9. Rizk MK, Sawhney MS, Cohen J, et al. Quality indicators common to all GI endoscopic procedures. Gastrointest Endosc 2015;81:3-16. https://doi.org/10.1016/j.gie.2014.07.055
  10. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-1399. https://doi.org/10.1053/j.gastro.2006.08.032
  11. Vogt JS, Larsen AC, Sommer T, Ejstrud P. Quality of endoscopic surveillance of Barrett's esophagus. Scand J Gastroenterol 2018;53:256-259. https://doi.org/10.1080/00365521.2018.1430251
  12. Han S, Yadlapati R, DeLay K, et al. Factors associated with suboptimal adherence to quality indicators in Barrett's esophagus. Gastroenterology 2018;154(6 Suppl 1):S-140.
  13. Ooi J, Wilson P, Walker G, et al. Dedicated Barrett's surveillance sessions managed by trained endoscopists improve dysplasia detection rate. Endoscopy 2017;49:524-528. https://doi.org/10.1055/s-0043-103410
  14. Sharma P, Hawes RH, Bansal A, et al. Standard endoscopy with random biopsies versus narrow band imaging targeted biopsies in Barrett's oesophagus: a prospective, international, randomised controlled trial. Gut 2013;62:15-21. https://doi.org/10.1136/gutjnl-2011-300962
  15. Shaheen NJ, Fennerty MB, Bergman JJ. Less is more: a minimalist approach to endoscopy. Gastroenterology 2018;154:1993-2003. https://doi.org/10.1053/j.gastro.2017.12.044
  16. Wani SB, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Over-utilization of repeat upper endoscopy in patients with non-dysplastic Barrett's esophagus: a population-based study using a national benchmarking registry. Gastroenterology 2018;154(6 Suppl 1):S28-S29.
  17. Tavakkoli A, Appelman HD, Beer DG, et al. Use of appropriate surveillance for patients with nondysplastic Barrett's esophagus. Clin Gastroenterol Hepatol 2018;16:862-869.e3. https://doi.org/10.1016/j.cgh.2018.01.052
  18. Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61:970-976. https://doi.org/10.1136/gutjnl-2011-300730
  19. Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009;7:736-742; quiz 710. https://doi.org/10.1016/j.cgh.2008.12.027
  20. Westerveld D, Khullar V, Mramba L, et al. Adherence to quality indicators and surveillance guidelines in the management of Barrett's esophagus: a retrospective analysis. Endosc Int Open 2018;6:E300-E307. https://doi.org/10.1055/s-0044-101351
  21. Wani SB, Williams JL, Komanduri S, Muthusamy VR, Shaheen NJ. Endoscopists biopsy the least those who need it the most: an analysis of Barrett's esophagus biopsy practices from a national quality benchmarking registry. Gastrointest Endosc 2018;87(6 Suppl):AB114.
  22. Wani SB, William JL, Komanduri S, Muthusamy VR, Shaheen NJ. Regional variations and trends in quality indicator (QI) performance in Barrett's esophagus (BE): results from a population-based study using a national benchmarking registry. Gastrointest Endosc 2018;87(6 Suppl):AB537.
  23. Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010;105:1523-1530. https://doi.org/10.1038/ajg.2010.171
  24. Qumseya BJ, Wani S, Gendy S, Harnke B, Bergman JJ, Wolfsen H. Disease progression in Barrett's low-grade dysplasia with radiofrequency ablation compared with surveillance: systematic review and meta-analysis. Am J Gastroenterol 2017;112:849-865. https://doi.org/10.1038/ajg.2017.70
  25. Scholvinck DW, van der Meulen K, Bergman JJGHM, Weusten BLAM. Detection of lesions in dysplastic Barrett's esophagus by community and expert endoscopists. Endoscopy 2017;49:113-120.
  26. Moss A, Bourke MJ, Hourigan LF, et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefit. Am J Gastroenterol 2010;105:1276-1283. https://doi.org/10.1038/ajg.2010.1
  27. Wani S, Mathur SC, Curvers WL, et al. Greater interobserver agreement by endoscopic mucosal resection than biopsy samples in Barrett's dysplasia. Clin Gastroenterol Hepatol 2010;8:783-788. https://doi.org/10.1016/j.cgh.2010.04.028
  28. Standards of Practice Committee, Wani S, Qumseya B, et al. Endoscopic eradication therapy for patients with Barrett's esophagus-associated dysplasia and intramucosal cancer. Gastrointest Endosc 2018;87:907-931.e9. https://doi.org/10.1016/j.gie.2017.10.011
  29. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008;57:1200-1206. https://doi.org/10.1136/gut.2007.142539
  30. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009;360:2277-2288. https://doi.org/10.1056/NEJMoa0808145
  31. Phoa KN, van Vilsteren FG, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and lowgrade dysplasia: a randomized clinical trial. JAMA 2014;311:1209-1217. https://doi.org/10.1001/jama.2014.2511
  32. Cotton CC, Haidry R, Thrift AP, Lovat L, Shaheen NJ. Development of evidence based surveillance intervals following radiofrequency ablation of Barrett's esophagus. Gastroenterology 2018 Apr 12 [Epub]. https://doi. org/10.1053/j.gastro.2018.04.011.
  33. van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy 2013;45:516-525. https://doi.org/10.1055/s-0032-1326423
  34. Komanduri S, Kahrilas PJ, Krishnan K, et al. Recurrence of Barrett's esophagus is rare following endoscopic eradication therapy coupled with effective reflux control. Am J Gastroenterol 2017;112:556-566. https://doi.org/10.1038/ajg.2017.13
  35. Qumseya BJ, Wani S, Desai M, et al. Adverse events after radiofrequency ablation in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016;14:1086-1095.e6. https://doi.org/10.1016/j.cgh.2016.04.001